Drug resistance hampers our capacity to roll back malaria
Drug resistance hampers our capacity to roll back malaria
复制标题
DOI：
10.1086/430785
复制
发表时间：
2005-08-15
影响因子：
11.8
通讯作者：
Olliaro, P
中科院分区：
文献类型：
--
作者：
Olliaro, P
寄生虫中广泛存在的耐药性加剧了疟疾的负担。这一问题的严重程度主要是由于迄今为止用于治疗疟疾的药物数量有限以及资源有限的政策和做法所致。所有正在使用的药物都受到影响，到目前为止，青蒿素衍生物除外。抗药性的规模和影响被低估，导致继续使用失败的药物，从而导致抗药性上升，疟疾的发病率和死亡率增加。药理学、流行病学和操作方面的因素是耐药性的发展和传播的因素。尽管问题很复杂，但要扭转事态的发展，可以做很多事情：采用适当的测试来评估耐药性，鼓励和维持新药的开发，通过联合使用保护药物免受耐药性的影响，扩大获得及时和有效治疗的机会，并促进循证政策和明智的做法。目前的形势有利于制定合理的战略来抑制阻力。
Widespread drug resistance in parasites aggravates the burden of malaria. The extent of the problem is due mainly to the limited armamentarium of drugs used thus far to treat malaria and to policies and practices constrained by limited resources. All drugs in use are affected except, thus far, artemisinin derivatives. The scale and impact of resistance has been underestimated, leading to the continued use of failing drugs, which contributes to the rise in resistance and increased morbidity and mortality due to malaria. Pharmacological, epidemiological, and operational aspects factor the development and spread of resistance. Although the problem is complex, much can be done to reverse the course of events: adopt adequate tests to assess resistance, encourage and sustain development of new drugs, protect drugs against resistance through use of combinations, expand access to prompt and effective treatment, and promote evidence-based policies and sensible practices. The current situation favors the development of sensible strategies to restrain resistance.